Published November 4, 2013
| Version Accepted Version
Journal Article
Open
Tailored Glycopolymers as Anticoagulant Heparin Mimetics
-
1.
California Institute of Technology
-
2.
The Ohio State University
Abstract
Not to clot: Heparin and its low-molecular-weight derivatives are clinical therapeutics used to treat and prevent blood clots. The synthesis of heparin-based glycopolymers that are potent and potentially safer mimetics of heparin is described. The mimetics exhibited activity against proteases (FXa and FIIa) in the coagulation cascade and prolonged blood clot times in human plasma with efficacies similar to those of clinical anticoagulants. ATIII=antithrombin III.
Additional Information
© 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. Received: August 8, 2013; Published online: October 9, 2013. We thank Prof. Robert H. Grubbs and Dr. Jean Li for their generous donation of the ruthenium catalyst and for helpful discussions. This research was supported by National Institutes of Health grant R01 GM093627 (L.H.W.).Attached Files
Accepted Version - nihms534450.pdf
Files
nihms534450.pdf
Additional details
Identifiers
- PMCID
- PMC3943734
- Eprint ID
- 42784
- Resolver ID
- CaltechAUTHORS:20131203-081421669
Funding
- NIH
- R01 GM093627
Dates
- Created
-
2013-12-03Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field